Morgan Stanley Poly Pid Ltd. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.34 - $0.45 $2,978 - $3,942	8,761 Added 23.8%	45,567 $16,000
Q1 2023 May 15, 2023	SELL	$0.4 - $1.08 $16,815 - $45,402	-42,039 Reduced 53.32%	36,806 $16,000
Q4 2022 Feb 14, 2023	BUY	$0.66 - $38.7 $4,375 - $256,542	6,629 Added 9.18%	78,845 $55,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $36.9 $32,369 - $1.13 Million	-30,537 Reduced 29.72%	72,216 $84,000
Q2 2022 Oct 27, 2022	BUY	$4.35 - $5.76 $24,742 - $32,762	5,688 Added 5.86%	102,753 $477,000
Q2 2022 Aug 15, 2022	BUY	$4.35 - $5.76 $24,742 - $32,762	5,688 Added 5.86%	102,753 $477,000
Q1 2022 Oct 27, 2022	SELL	$3.92 - $6.25 $22,296 - $35,550	-5,688 Reduced 5.54%	97,065 $530,000
Q1 2022 May 13, 2022	BUY	$3.92 - $6.25 $306,736 - $489,056	78,249 Added 415.86%	97,065 $530,000
Q4 2021 Feb 14, 2022	BUY	$5.52 - $8.42 $87,304 - $133,170	15,816 Added 527.2%	18,816 $108,000
Q3 2021 Nov 15, 2021	BUY	$7.05 - $9.48 $21,150 - $28,440	3,000 New	3,000 $24,000

Ticker PYPD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,551,200
Market Cap $69.6M
Description
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well a...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.